https://scholars.lib.ntu.edu.tw/handle/123456789/635778| Title: | Brigatinib Versus Alectinib in ALK-Positive NSCLC After Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 Trial | Authors: | CHIH-HSIN YANG Liu, Geoffrey Lu, Shun He, Jianxing Burotto, Mauricio Ahn, Myung-Ju Kim, Dong-Wan Liu, XiaoQing Zhao, Yanqiu Vincent, Sylvie Yin, Jiani Ma, Xin Lin, Huamao M Popat, Sanjay |
Keywords: | Alectinib; Anaplastic lymphoma kinase; Brigatinib; Non–small cell lung cancer; Tyrosine kinase inhibitor | Issue Date: | 12-Aug-2023 | Source: | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | Abstract: | This open-label, phase 3 trial (ALTA-3; NCT03596866) compared efficacy and safety of brigatinib versus alectinib for ALK+ NSCLC after disease progression on crizotinib. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/635778 | ISSN: | 15560864 | DOI: | 10.1016/j.jtho.2023.08.010 |
| Appears in Collections: | 腫瘤醫學研究所 |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.